Published in J Neurochem on March 17, 2010
Inhibition of mitochondrial fragmentation diminishes Huntington's disease-associated neurodegeneration. J Clin Invest (2013) 1.83
Proteostasis of polyglutamine varies among neurons and predicts neurodegeneration. Nat Chem Biol (2013) 1.52
Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology (2013) 1.18
Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics (2012) 0.98
The ubiquitin proteasome system in glia and its role in neurodegenerative diseases. Front Mol Neurosci (2014) 0.96
Modeling Huntington's disease with induced pluripotent stem cells. Mol Cell Neurosci (2013) 0.94
Cortical metabolites as biomarkers in the R6/2 model of Huntington's disease. J Cereb Blood Flow Metab (2011) 0.91
Transcellular spreading of huntingtin aggregates in the Drosophila brain. Proc Natl Acad Sci U S A (2015) 0.90
Translating neurobehavioural endpoints of developmental neurotoxicity tests into in vitro assays and readouts. Neurotoxicology (2011) 0.90
Impaired heat shock response in cells expressing full-length polyglutamine-expanded huntingtin. PLoS One (2012) 0.90
Axonal transport and neurodegenerative disease: can we see the elephant? Prog Neurobiol (2012) 0.87
Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains. Hum Mol Genet (2014) 0.85
Mutant huntingtin downregulates myelin regulatory factor-mediated myelin gene expression and affects mature oligodendrocytes. Neuron (2015) 0.85
Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats. PLoS One (2013) 0.84
Early deficits in glycolysis are specific to striatal neurons from a rat model of huntington disease. PLoS One (2013) 0.84
Deep white matter in Huntington's disease. PLoS One (2014) 0.83
The Ubiquitin-Proteasome System in Huntington's Disease: Are Proteasomes Impaired, Initiators of Disease, or Coming to the Rescue? Biochem Res Int (2012) 0.83
Protection by glia-conditioned medium in a cell model of Huntington disease. PLoS Curr (2012) 0.83
Restricted transgene expression in the brain with cell-type specific neuronal promoters. Hum Gene Ther Methods (2012) 0.83
Cell type-specific spatial and functional coupling between mammalian brain Kv2.1 K+ channels and ryanodine receptors. J Comp Neurol (2014) 0.83
Huntington's Disease: From Mutant Huntingtin Protein to Neurotrophic Factor Therapy. Int J Biomed Sci (2011) 0.82
Specific reactions of different striatal neuron types in morphology induced by quinolinic acid in rats. PLoS One (2014) 0.82
Analysis of YFP(J16)-R6/2 reporter mice and postmortem brains reveals early pathology and increased vulnerability of callosal axons in Huntington's disease. Hum Mol Genet (2015) 0.81
The role of the cofilin-actin rod stress response in neurodegenerative diseases uncovers potential new drug targets. Bioarchitecture (2012) 0.80
Melatonin ameliorates injury and specific responses of ischemic striatal neurons in rats. J Histochem Cytochem (2013) 0.80
The mechanism of degeneration of striatal neuronal subtypes in Huntington disease. Ann Neurosci (2014) 0.80
Rhes: a GTP-binding protein integral to striatal physiology and pathology. Cell Mol Neurobiol (2012) 0.79
Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington's disease. Mol Ther Methods Clin Dev (2016) 0.77
Striatal oligodendrogliogenesis and neuroblast recruitment are increased in the R6/2 mouse model of Huntington's disease. Brain Res (2013) 0.77
Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal Models. Front Neurosci (2016) 0.75
Voluntary saccade inhibition deficits correlate with extended white-matter cortico-basal atrophy in Huntington's disease. Neuroimage Clin (2017) 0.75
Protective Effects of Aqueous Extract of Luehea divaricata against Behavioral and Oxidative Changes Induced by 3-Nitropropionic Acid in Rats. Evid Based Complement Alternat Med (2015) 0.75
Transcriptome tomography for brain analysis in the web-accessible anatomical space. PLoS One (2012) 0.75
Oscillating PDF in termini of circadian pacemaker neurons and synchronous molecular clocks in downstream neurons are not sufficient for sustenance of activity rhythms in constant darkness. PLoS One (2017) 0.75
The heat shock response in neurons and astroglia and its role in neurodegenerative diseases. Mol Neurodegener (2017) 0.75
Regulation of motor proteins, axonal transport deficits and adult-onset neurodegenerative diseases. Neurobiol Dis (2017) 0.75
Oxidative metabolism and Ca(2+) handling in striatal mitochondria from YAC128 mice, a model of Huntington's disease. Neurochem Int (2017) 0.75
The functional anatomy of basal ganglia disorders. Trends Neurosci (1989) 12.28
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature (2004) 11.82
Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (1997) 11.53
Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell (1997) 9.57
Trinucleotide repeat disorders. Annu Rev Neurosci (2007) 9.45
D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science (1990) 8.07
Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol (1985) 7.93
Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell (1998) 7.13
Integrated analysis of protein composition, tissue diversity, and gene regulation in mouse mitochondria. Cell (2003) 6.77
Mitochondria: more than just a powerhouse. Curr Biol (2006) 6.76
Huntington disease. J Neuropathol Exp Neurol (1998) 6.54
Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet (1993) 6.53
The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat Genet (1993) 5.82
Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat Genet (1993) 5.70
Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell (2004) 5.67
Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature (1997) 5.29
Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science (2001) 5.28
Mutant dynactin in motor neuron disease. Nat Genet (2003) 5.28
Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Brain Res Rev (1995) 5.23
Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science (2003) 4.40
Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathology. J Neurosci (1999) 4.27
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci (2002) 4.15
Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron (2003) 4.04
CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol (1997) 4.01
DCTN1 mutations in Perry syndrome. Nat Genet (2009) 3.87
Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience (1998) 3.70
Striatal interneurones: chemical, physiological and morphological characterization. Trends Neurosci (1995) 3.65
Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci (2008) 3.54
Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell (1995) 3.45
Ageing and neuronal vulnerability. Nat Rev Neurosci (2006) 3.36
The origins of two-state spontaneous membrane potential fluctuations of neostriatal spiny neurons. J Neurosci (1996) 3.20
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron (1995) 3.08
Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet (2000) 3.07
A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet (2002) 2.98
The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci (1992) 2.89
The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. Am J Hum Genet (1997) 2.84
Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci (1990) 2.83
Differential loss of striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A (1988) 2.78
Axonal transport defects in neurodegenerative diseases. J Neurosci (2009) 2.74
Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol (2004) 2.65
Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol (1997) 2.64
Cell death in the nervous system. Nature (2006) 2.62
The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell (2002) 2.56
Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron (2003) 2.50
Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet (1998) 2.39
Distal spinal and bulbar muscular atrophy caused by dynactin mutation. Ann Neurol (2005) 2.34
Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat Genet (1995) 2.33
Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci (2003) 2.31
Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J Neurosci (2001) 2.29
Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci (1993) 2.27
N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci (2008) 2.18
Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol (2007) 2.17
Selective sparing of a class of striatal neurons in Huntington's disease. Science (1985) 2.16
Early striatal dendrite deficits followed by neuron loss with advanced age in the absence of anterograde cortical brain-derived neurotrophic factor. J Neurosci (2004) 2.16
JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci (2006) 2.11
Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol (1996) 2.09
Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature (1976) 2.08
Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc Natl Acad Sci U S A (2004) 2.00
The corticostriatal pathway in Huntington's disease. Prog Neurobiol (2006) 1.99
Dramatic tissue-specific mutation length increases are an early molecular event in Huntington disease pathogenesis. Hum Mol Genet (2003) 1.96
HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism. Hum Mol Genet (2005) 1.96
Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiol Dis (1998) 1.96
Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol (1992) 1.96
Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat Neurosci (2009) 1.95
Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci (1976) 1.92
Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol (2001) 1.91
Huntington aggregates may not predict neuronal death in Huntington's disease. Ann Neurol (1999) 1.91
Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci (2003) 1.88
Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology (1993) 1.88
A cellular model that recapitulates major pathogenic steps of Huntington's disease. Hum Mol Genet (1998) 1.87
The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol (1998) 1.87
Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci (1999) 1.86
Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Hum Mol Genet (1999) 1.86
Transcriptional signatures in Huntington's disease. Prog Neurobiol (2007) 1.86
Global deprivation of brain-derived neurotrophic factor in the CNS reveals an area-specific requirement for dendritic growth. J Neurosci (2010) 1.85
The neostriatal mosaic: compartmental distribution of calcium-binding protein and parvalbumin in the basal ganglia of the rat and monkey. Proc Natl Acad Sci U S A (1985) 1.83
Huntington's disease: the challenge for cell biologists. Trends Cell Biol (2000) 1.80
Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases. FEBS J (2008) 1.79
Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington's disease patients. Ann Neurol (1995) 1.79
Distribution of striatonigral and striatopallidal peptidergic neurons in both patch and matrix compartments: an in situ hybridization histochemistry and fluorescent retrograde tracing study. Brain Res (1988) 1.78
Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci (2004) 1.76
NMDA receptor function in mouse models of Huntington disease. J Neurosci Res (2001) 1.76
Axonal transport defects: a common theme in neurodegenerative diseases. Acta Neuropathol (2005) 1.76
Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci (2000) 1.75
Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection". Neuroimage (2009) 1.72
Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J Biol Chem (2002) 1.70
Huntington's disease gene (IT15) is widely expressed in human and rat tissues. Neuron (1993) 1.69
Pathogenesis of polyglutamine disorders: aggregation revisited. Hum Mol Genet (2003) 1.67
Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc Natl Acad Sci U S A (2000) 1.66
Transgenic rat model of Huntington's disease. Hum Mol Genet (2003) 1.66
Akt1 regulates a JNK scaffold during excitotoxic apoptosis. Neuron (2002) 1.65
Glutamine repeats and inherited neurodegenerative diseases: molecular aspects. Curr Opin Struct Biol (1996) 1.63
Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat Neurosci (2008) 1.63
Neostriatal cell subtypes and their functional roles. Neurosci Res (1997) 1.60
Dramatic mutation instability in HD mouse striatum: does polyglutamine load contribute to cell-specific vulnerability in Huntington's disease? Hum Mol Genet (2000) 1.58
Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect. Trends Neurosci (2004) 1.58
Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci (2004) 1.58
Triplet repeat mutation length gains correlate with cell-type specific vulnerability in Huntington disease brain. Hum Mol Genet (2007) 1.57
Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington's disease. J Neurosci (2001) 1.52
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90
A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol (2003) 6.21
Wild-type and mutant SOD1 share an aberrant conformation and a common pathogenic pathway in ALS. Nat Neurosci (2010) 4.25
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol (2002) 3.84
A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med (2005) 3.46
Missing pieces in the Parkinson's disease puzzle. Nat Med (2010) 2.90
Axonal transport defects in neurodegenerative diseases. J Neurosci (2009) 2.74
Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J (2002) 2.70
Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron (2003) 2.50
Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2007) 2.43
Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol Dis (2006) 2.23
Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol (2006) 2.17
JNK mediates pathogenic effects of polyglutamine-expanded androgen receptor on fast axonal transport. Nat Neurosci (2006) 2.11
Axonal transport, amyloid precursor protein, kinesin-1, and the processing apparatus: revisited. J Neurosci (2005) 2.04
Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat Neurosci (2009) 1.95
The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci (2003) 1.92
Alzheimer's presenilin 1 mutations impair kinesin-based axonal transport. J Neurosci (2003) 1.91
Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions. Neurobiol Dis (2009) 1.90
Reelin-mediated signaling locally regulates protein kinase B/Akt and glycogen synthase kinase 3beta. J Biol Chem (2002) 1.88
Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord (2011) 1.87
Transglutaminase and polyamination of tubulin: posttranslational modification for stabilizing axonal microtubules. Neuron (2013) 1.78
Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord (2012) 1.76
A novel CDK5-dependent pathway for regulating GSK3 activity and kinesin-driven motility in neurons. EMBO J (2004) 1.71
The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res (2009) 1.65
Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Neurosurgery (2002) 1.54
Estrogen increases the number of spinophilin-immunoreactive spines in the hippocampus of young and aged female rhesus monkeys. J Comp Neurol (2003) 1.49
Estrogen replacement increases spinophilin-immunoreactive spine number in the prefrontal cortex of female rhesus monkeys. Cereb Cortex (2004) 1.48
Ageing as a primary risk factor for Parkinson's disease: evidence from studies of non-human primates. Nat Rev Neurosci (2011) 1.45
Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One (2011) 1.40
Impairments in fast axonal transport and motor neuron deficits in transgenic mice expressing familial Alzheimer's disease-linked mutant presenilin 1. J Neurosci (2007) 1.39
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord (2010) 1.39
Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases. J Neurosci (2011) 1.39
Human neural stem cell transplants improve motor function in a rat model of Huntington's disease. J Comp Neurol (2004) 1.35
Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol (2002) 1.32
Quantitative and functional analyses of spastin in the nervous system: implications for hereditary spastic paraplegia. J Neurosci (2008) 1.32
Neurotrophic factor therapy for Parkinson's disease. Prog Brain Res (2010) 1.30
Fast axonal transport misregulation and Alzheimer's disease. Neuromolecular Med (2002) 1.28
Nurr1 in Parkinson's disease and related disorders. J Comp Neurol (2006) 1.27
Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis (2007) 1.26
Conventional kinesin holoenzymes are composed of heavy and light chain homodimers. Biochemistry (2008) 1.25
Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol (2004) 1.23
Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain (2012) 1.22
Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J Comp Neurol (2002) 1.19
Regulation of cyclic AMP response element binding and hippocampal plasticity-related genes by peroxisome proliferator-activated receptor α. Cell Rep (2013) 1.19
Ca2+-dependent dephosphorylation of kinesin heavy chain on beta-granules in pancreatic beta-cells. Implications for regulated beta-granule transport and insulin exocytosis. J Biol Chem (2002) 1.19
Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology (2013) 1.18
Tau binding to microtubules does not directly affect microtubule-based vesicle motility. J Neurosci Res (2007) 1.17
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis (2007) 1.15
Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther (2009) 1.14
Age-related accumulation of Marinesco bodies and lipofuscin in rhesus monkey midbrain dopamine neurons: relevance to selective neuronal vulnerability. J Comp Neurol (2007) 1.11
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery (2009) 1.10
Proteasome inhibition and Parkinson's disease modeling. Ann Neurol (2006) 1.10
Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci (2002) 1.10
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord (2007) 1.10
Chronic ischemic stroke model in cynomolgus monkeys: behavioral, neuroimaging and anatomical study. Neurol Res (2003) 1.09
Lewy body pathology in fetal grafts. Ann N Y Acad Sci (2010) 1.08
Polyglutamine expansion diseases: failing to deliver. Trends Mol Med (2005) 1.08
Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp Neurol (2005) 1.06
Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport. Biochemistry (2011) 1.05
Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport. Neurobiol Aging (2011) 1.04
Transport of neurofilaments in growing axons requires microtubules but not actin filaments. J Neurosci Res (2005) 1.03
Doublecortin expression in adult cat and primate cerebral cortex relates to immature neurons that develop into GABAergic subgroups. Exp Neurol (2008) 1.03
Gene therapy for Parkinson's disease. Mov Disord (2010) 1.02
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis (2011) 1.02
Trophic factors therapy in Parkinson's disease. Prog Brain Res (2009) 1.02
Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis (2005) 1.01
Animal models of Huntington's disease. ILAR J (2007) 1.01
Reelin and cyclin-dependent kinase 5-dependent signals cooperate in regulating neuronal migration and synaptic transmission. J Neurosci (2004) 1.00
Prenatal 3,4-methylenedioxymethamphetamine (ecstasy) alters exploratory behavior, reduces monoamine metabolism, and increases forebrain tyrosine hydroxylase fiber density of juvenile rats. Neurotoxicol Teratol (2003) 0.99
Dopaminergic transplantation for Parkinson's disease: current status and future prospects. Ann Neurol (2009) 0.98
Testing NF-κB-based therapy in hemiparkinsonian monkeys. J Neuroimmune Pharmacol (2012) 0.98
Molecular mechanisms of environmental enrichment: impairments in Akt/GSK3β, neurotrophin-3 and CREB signaling. PLoS One (2013) 0.97
Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLoS One (2013) 0.97
The sphingolipid psychosine inhibits fast axonal transport in Krabbe disease by activation of GSK3β and deregulation of molecular motors. J Neurosci (2013) 0.97
Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A (2006) 0.96
Activity-driven dendritic remodeling requires microtubule-associated protein 1A. Curr Biol (2005) 0.96
Doublecortin-expressing cells persist in the associative cerebral cortex and amygdala in aged nonhuman primates. Front Neuroanat (2009) 0.95
Axonal degeneration in Alzheimer's disease: when signaling abnormalities meet the axonal transport system. Exp Neurol (2012) 0.95
Role of heparin binding growth factors in nigrostriatal dopamine system development and Parkinson's disease. Brain Res (2007) 0.95
GFAP knockout mice have increased levels of GDNF that protect striatal neurons from metabolic and excitotoxic insults. J Comp Neurol (2003) 0.95
Molecular chaperone Hsp110 rescues a vesicle transport defect produced by an ALS-associated mutant SOD1 protein in squid axoplasm. Proc Natl Acad Sci U S A (2013) 0.94
Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther (2008) 0.94
Gene therapy for Huntington's disease. Neurobiol Dis (2011) 0.94
Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. Exp Neurol (2003) 0.94
Cellular trafficking of phospholamban and formation of functional sarcoplasmic reticulum during myocyte differentiation. Am J Physiol Cell Physiol (2007) 0.94
Future of cell and gene therapies for Parkinson's disease. Ann Neurol (2008) 0.92
Cell transplantation and gene therapy in Parkinson's disease. Mt Sinai J Med (2011) 0.91
Huntington's disease: pathological mechanisms and therapeutic strategies. Cell Transplant (2007) 0.91
Etiology of Parkinson's disease: Genetics and environment revisited. Proc Natl Acad Sci U S A (2002) 0.91